-
Ablynx is a
subsidiary of
biopharmaceutical company Sanofi engaged in the
discovery and
development of nanobodies,
based in
Science Park Zwijnaarde, Ghent...
-
offered to
acquire Ablynx for $3.1
billion -
having made an
unreported offer in mid-December for the company. However, the
Ablynx board rejected this...
- 20 listings, with the
exception a one-month
period in May–June 2018 when
Ablynx stock was
removed following the
takeover by Sanofi, only to be replaced...
-
Bioverativ for $11.6
billion and days
later announced that it
would acquire Ablynx for €3.9
billion ($4.8 billion). In
December 2019, the
company announced...
-
thrombocytopenic purpura (TTP) and thrombosis. This drug was
developed by
Ablynx NV. On 30
August 2018, it was
approved in the
European Union for the "treatment...
- diseases.
Ozoralizumab was
developed by
Pfizer Inc, and now
belongs to
Ablynx NV.
Ablynx has
licensed the
rights to the
antibody in
China to Eddingpharm. In...
- The
Ghent University and
several research-oriented companies, such as
Ablynx, Innogenetics, Cropdesign, and
Bayer Cropscience, are
situated in the central...
-
Global 500". Fortune. "Llama-Based
Biotechnology Draws New
Interest to
Ablynx". Bloomberg. 2015-05-13.
Retrieved 2017-12-20. "Alpro -
About Alpro". www...
-
January 2015,
Merck acquired Cubist Pharmaceuticals. In July 2015,
Merck and
Ablynx expanded their 18-month-old immuno-oncology
collaboration by four years...
-
treatment of
inflammatory autoimmune diseases. This drug was
developed by
Ablynx NV to
block interleukin-6 receptor.
Vobarilizumab has been
evaluated in...
